Physician profile
Eric Eugene Evans
NPI 1407808314
$10,130.77
in general payments reported to CMS, 2019-2025
20 companies · $1,307 in 2025
The $1,307 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,257 · 2022: $1,798 · 2023: $3,994 · 2024: $1,775 · 2025: $1,307.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,004 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,525 · Education: $395 · Travel and Lodging: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,003.60 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,525.00 |
| Education | $395.47 |
| Travel and Lodging | $151.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $4,773.36 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Abbvie INC. | $1,347.67 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $816.46 | 2022-2025 | Qelbree, Qelbree |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $693.75 | 2022-2025 | Caplyta |
| Alkermes, INC. | $685.86 | 2021-2025 | Aristada, Lybalvi |
| Neurocrine Biosciences, INC. | $289.02 | 2024-2025 | Ingrezza |
| Otsuka America Pharmaceutical, INC. | $279.74 | 2021-2025 | Rexulti |
| Corium, LLC | $244.30 | 2022-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $205.36 | 2022-2023 | Jornay Pm |
| Sunovion Pharmaceuticals INC. | $153.62 | 2021-2022 | |
| Luye Pharma (USA) LTD. | $146.35 | 2025 | Erzofri Extended-Release |
| Vanda Pharmaceuticals INC. | $102.97 | 2021-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $99.24 | 2021-2023 | Spravato |
| Eisai INC. | $82.12 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $59.81 | 2024-2025 | Cobenfy |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $51.47 | 2022-2024 | Rexulti |
| Idorsia Pharmaceuticals US INC | $51.44 | 2022-2024 | Quviviq |
| Axsome Therapeutics, INC. | $18.31 | 2024 | Auvelity |
| Tris Pharma INC | $15.57 | 2023 | Dyanavel Xr |
| Indivior INC. | $14.35 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.